

ALTERNATIVE TO THE TREATMENT OF POOR GRAFT FUNCTION AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: ELTROMBOPAG

MONTERO ANTÓN, M.D.P.; COLLADO BORRELL, R.; ESCUDERO VILAPLANA, V.; REVUELTA HERRERO, J.L.; VILLANUEVA BUENO, C.; RIOJA DIEZ, Y.; PRIETO ROMERO, A.; CARRILLO BURDALLO, A.; SOMOZA FERNANDEZ, B.; HERRANZ ALONSO, A.; SANJURJO SAEZ, M.

Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Madrid, Spain

AIM AND OBJECTIVES

Poor graft function is a rare and serious complication in patients who have undergone haematopoietic stem cell transplantation (HSCT). Currently, treatment options are very limited and not without complications.

Our aim is to evaluate the effectiveness of eltrombopag as an off-label indication in patients with poor graft function who have undergone HSCT.


MATERIALS AND METHODS

Observational, retrospective, longitudinal study in which the effectiveness and safety of eltrombopag was evaluated in patients with poor graft function who received HSCT between January 2018 - January 2023. Patients were analysed from the start of eltrombopag until recovery of function and/or death.

Poor graft function was defined as the presence of sustained thrombopenia ($<20 \times 10^9/L$) despite transfusion support. Effectiveness was assessed by the overall haematological response rate: platelet recovery (platelets $>50 \times 10^9/L$ for >4 weeks).

Data analysis was performed using SPSS 21.0 statistical software. Variables were analysed using descriptive statistics.

RESULTS



CONCLUSION AND RELEVANCE

Among the few existing therapeutic alternatives for thrombopenia resulting from poor graft function, the use of eltrombopag shows response rates close to 60%, so it appears to be an effective alternative.